JERSEY CITY

AvePoint Announces First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 9, 2024
Public sector, Total, Investment, ARR, Average cost, Certification, Webcast, Software as a service, Entrepreneurship, FedRAMP, AvePoint, HITRUST, First officer (aviation), Microsoft, SOC, Data management, FX, GAAP, Growth, Video game

JERSEY CITY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- AvePoint (NASDAQ: AVPT), a global leader in robust data management and data governance, today announced financial results for the first quarter ended March 31, 2024. 

Key Points: 
  • First quarter SaaS revenue of $51.3 million, representing 44% year-over-year growth
    First quarter Total revenue of $74.5 million, representing 25% year-over-year growth
    Total ARR of $274.5 million, representing 23% year-over-year growth
    JERSEY CITY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- AvePoint (NASDAQ: AVPT), a global leader in robust data management and data governance, today announced financial results for the first quarter ended March 31, 2024.
  • Gross Profit: GAAP gross profit was $54.1 million, compared to $41.7 million for the first quarter of 2023.
  • For the second quarter of 2024, the Company expects:
    Total revenues of $73.8 million to $75.8 million, or year-over-year growth of 15% at the midpoint.
  • AvePoint will host a conference call today, May 9, 2024, to review its first quarter 2024 financial results and to discuss its financial outlook.

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 8, 2024
Infection, Congress, Candida glabrata, Investment, Mouse, Data analysis, NIH, Fungal infection, Research, ECCMID, Clinical trial, FURI, GSK, Antimalarial medication, Patient, Candidiasis, CMC, Chemistry, National Institutes of Health, Candida auris, Biotechnology, Mucorales, Pharmaceutical industry

Phase I-enabling development activities for SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to progress.

Key Points: 
  • Phase I-enabling development activities for SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to progress.
  • Research and development expense for the quarter ended March 31, 2024 was $7.2 million compared to $6.8 million for the same period in 2023.
  • SG&A expense for the quarter ended March 31, 2024 decreased to $3.7 million from $4.8 million for the same period in 2023.
  • Cash, cash equivalents and investments totaled $94.2 million on March 31, 2024, compared to $98.0 million on December 31, 2023.

Blossom Dispensary: The Destination Cannabis Dispensary in The Heights Jersey City, New Jersey

Retrieved on: 
Monday, May 6, 2024
U.S. Route 1/9, Lincoln Tunnel, Travel, MWBE, Holland Tunnel, American Dream, Cannabis, Minority, MetLife Stadium, Overalls, Drug

JERSEY CITY, N.J., May 6, 2024 /PRNewswire/ -- The destination dispensary for cannabis connoisseurs has opened its doors in The Heights Jersey City.

Key Points: 
  • JERSEY CITY, N.J., May 6, 2024 /PRNewswire/ -- The destination dispensary for cannabis connoisseurs has opened its doors in The Heights Jersey City.
  • Bina Bhatt, a Jersey City resident of over 25 years, infuses Blossom Dispensary with her wealth of experience in management, operations, and compliance.
  • As an accredited MWBE (Minority and Women Business Enterprise) in New Jersey, Blossom Dispensary underscores its commitment to diversity, quality, and community involvement.
  • The team at Blossom Dispensary is dedicated to helping customers grasp the numerous benefits that cannabis can offer.

AvePoint to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, May 2, 2024
Goldman Sachs, Virtual, Conference, Software as a service, AvePoint, ISI

JERSEY CITY, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT), the most advanced platform to optimize SaaS operations and secure collaboration, today announced that members of the company’s executive management team will present at the following investor conferences:

Key Points: 
  • JERSEY CITY, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT), the most advanced platform to optimize SaaS operations and secure collaboration, today announced that members of the company’s executive management team will present at the following investor conferences:
    19th Annual Needham Technology, Media, & Consumer Conference (New York, NY): Tuesday, 5/14 at 2:15 pm ET
    TD Cowen 52nd Annual Technology, Media & Telecom Conference (New York, NY): Wednesday, 5/29 at 10:50 am ET
    Jefferies Software Conference (Newport Coast, CA): Wednesday, 5/29 at 10:30am PT
    William Blair 44th Annual Growth Stock Conference (Chicago, IL): Tuesday, 6/4 at 9:20am CT
    In addition, AvePoint will attend the following conferences:
    Evercore ISI Microsoft 360° Day (Virtual): Wednesday, 5/15
    Goldman Sachs TechNet Conference Asia Pacific 2024 (Hong Kong, CN): Tuesday, 5/21
    A live and archived audio webcast of all presentations will be available on the AvePoint Investor Relations website.

New Jersey Customer Wins Big With Lotto.com and Pledges to Donate to Local Charities

Retrieved on: 
Tuesday, April 23, 2024
News, Jersey, Organic

The lucky winner and frequent customer on Lotto.com learned the exciting news during their morning commute, when they were notified that they had won $208,940.

Key Points: 
  • The lucky winner and frequent customer on Lotto.com learned the exciting news during their morning commute, when they were notified that they had won $208,940.
  • The notification tool is a helpful feature on Lotto.com that quickly informs customers of their wins and also keeps them up-to-date with local and national jackpot news and lottery promotions.
  • Everything you need is there; you just click on the numbers you want and it goes right through,” stated the customer.
  • With their prize money, the winning Lotto.com customer is looking forward to donating to local charities and helping people in need.

CEX.IO’s Mark Taylor, Global Head of Financial Crime to Join Panel Organized by C5

Retrieved on: 
Tuesday, April 23, 2024
Crypto, Decentralized finance, Public sector, Recovery, Ecosystem, Fraud, C5, Financial crime, Private, Environment, Database, The Fight, Cryptocurrency

Panelists will explore successful attempts at digital asset recovery, and reveal the necessary levers required for cross-platform and multi-jurisdictional collaboration to assist in these efforts.

Key Points: 
  • Panelists will explore successful attempts at digital asset recovery, and reveal the necessary levers required for cross-platform and multi-jurisdictional collaboration to assist in these efforts.
  • The panel will take place on Friday, 26 April from 12:45 - 13:30 at The Millennium Gloucester Hotel, 4-18 Harrington Gardens, South Kensington, London.
  • “For too long, bad actors have felt empowered to exploit undefined parameters in the crypto ecosystem, often at the disadvantage of unsuspecting participants,” Taylor said.
  • Launched by C5 , Crypto and Digital Asset Fraud & Recovery aims to unite people power with data-driven solutions in an effort to build more harmonious online spaces.

AvePoint to Announce First Quarter 2024 Financial Results on May 9

Retrieved on: 
Thursday, April 18, 2024
Entrepreneurship, AvePoint, Calendar, Webcast, Software as a service

JERSEY CITY, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- AvePoint (NASDAQ: AVPT), the most advanced platform to optimize SaaS operations and secure collaboration, will report its first quarter 2024 financial results after the US financial markets close on Thursday, May 9, 2024.

Key Points: 
  • JERSEY CITY, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- AvePoint (NASDAQ: AVPT), the most advanced platform to optimize SaaS operations and secure collaboration, will report its first quarter 2024 financial results after the US financial markets close on Thursday, May 9, 2024.
  • The company will host a conference call at 4:30pm ET on Thursday, May 9, 2024.
  • CEO and Co-Founder Dr. Tianyi Jiang (TJ) and CFO Jim Caci will provide an overview of these results, discuss current business trends, and conduct a question-and-answer session.
  • A live webcast will be available in the Investor Relations section of AvePoint’s website at: https://ir.avepoint.com/events .

Verisk to Announce Fiscal First-Quarter 2024 Results on May 1, 2024

Retrieved on: 
Wednesday, April 10, 2024
Webcast, VRSK, Conference

JERSEY CITY, N.J., April 10, 2024 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, will report its financial results for the fiscal first quarter ended on Sunday, March 31, 2024, on Wednesday, May 1, 2024, before the market open.

Key Points: 
  • JERSEY CITY, N.J., April 10, 2024 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, will report its financial results for the fiscal first quarter ended on Sunday, March 31, 2024, on Wednesday, May 1, 2024, before the market open.
  • The press release, with accompanying financial information, will be posted on the Verisk investor website at https://investor.verisk.com .
  • Verisk’s management team will host a live audio webcast to discuss the financial results and business highlights on Wednesday, May 1 at 8:30 a.m.
  • All interested parties are invited to listen to the live event via webcast on the Verisk investor website at https://investor.verisk.com .

AvePoint Launches New Analytics Capabilities for Copilot for Microsoft 365

Retrieved on: 
Tuesday, April 9, 2024
Microsoft, HR, ROI, Organization, Software as a service, Forrester Research, Workforce, Role, Geography, AvePoint, Data management, Video game

To maximize the potential of Copilot for Microsoft 365 to accelerate innovation and productivity, AvePoint tyGraph enables organizations to:

Key Points: 
  • To maximize the potential of Copilot for Microsoft 365 to accelerate innovation and productivity, AvePoint tyGraph enables organizations to:
    Gain Insights into Copilot for Microsoft 365 Usage: Organizations can now unlock valuable data-driven intelligence about how workers leverage Microsoft's AI-powered productivity tool by tracking adoption trends over time, pinpointing untapped opportunities for increased engagement, and comparing Copilot for Microsoft 365 usage across the organization.
  • AvePoint tyGraph Copilot for Microsoft 365 Adoption Analytics is the latest addition to AvePoint's Copilot for Microsoft 365 data readiness solutions , which help organizations prepare, secure, and optimize their data for Copilot for Microsoft 365.
  • “AvePoint tyGraph has always provided unparalleled Microsoft 365 analytics to maximize return on Microsoft investment,” said John Peluso, Chief Technology Officer, AvePoint.
  • We firmly believe that the analytics from AvePoint tyGraph, along with all our Copilot for Microsoft 365 data readiness solutions, will help organizations to fully take advantage of AI in the workplace.”
    For more information on AvePoint tyGraph’s new capabilities for Copilot for Microsoft 365, visit the AvePoint website .

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Tuesday, April 9, 2024
Antimalarial medication, Polyene, Fungal infection, Candidiasis, Congress, Biotechnology, Azole, Candida auris, Patient, Mouse, Infection, University, NOS, Echinocandin, University of Texas System, Fluconazole, ECCMID, European, Candida glabrata, Pharmaceutical industry

These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.

Key Points: 
  • These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.
  • Candida auris is an emerging fungal pathogen associated with nosocomial infections and considered a serious global health threat.
  • The work here utilized the National Institute of Allergy and Infectious Diseases’ (NIAID’s) suite of preclinical services for in vivo testing (Contract Nos.
  • SCY-247, a novel second-generation IV/oral triterpenoid antifungal, demonstrates in vitro activity against fungal pathogens, including azole-resistant strains of Candida and Aspergillus